InvivoCrown In vivo depletion

InVivoPro Anti-Mouse CTLA-4 (CD152) in vivo antibody, Clone 9H10InVivoPro Anti-Mouse Ly6G/Ly6C (Gr-1) in vivo antibody, Clone RB6-8C5Syrian hamster IgGRat IgG2b9H10RB6-8C5CTLA-4Ly6G/Ly6Ccytotoxic T-lymphocyte antigen 4, CTLA-4, CD152Ly-6G/LY-6C, Gr-1Syrian hamster lgG Isotype ControlIV0106 or Rat IgG2b Isotype Control PBS, pH 7.2, contains no stabilizers or preservativesPBS, pH 7.2, contains no stabilizers or preservativesMouseMouseSyrian hamsterRat200-300 μg per mouse; or 10-15 mg/kg. This range is based off the most recent publication data using the 9H10 clone in vivo. Each investigator should determine their own optimal working dilution for specific applications.200-500 μg per mouse; or 10-20 mg/kg. This range is based off the most recent publication data using the RB6-8C5 clone in vivo. Each investigator should determine their own optimal working dilution for specific applications.176200Gao, Jianjun et al. "Loss of IFN-γ Pathway Genes in Tumor Cells As a Mechanism of Resistance to Anti-CTLA-4 Therapy.",Cell 167.2 (2016): 397-404.e9. Benci, Joseph L. et al. "Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade.",Cell 167.6 (2016): 1540-1554.e12. Jerby-Arnon, Livnat, et al. "A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade." Cell 175.4 (2018): 984-997.Ali, Niwa, et al. "Regulatory T cells in skin facilitate epithelial stem cell differentiation." Cell 169.6 (2017): 1119-1129. Miao, Yuxuan, et al. "Adaptive immune resistance emerges from tumor-initiating stem cells." Cell 177.5 (2019): 1172-1186. Ortiz-Muñoz, Guadalupe et al. "In Situ Tumour Arrays Reveal Early Environmental Control of Cancer Immunity.",NATURE 618.7966 (2023): 827-+.CTLA4 (Cytotoxic T-Lymphocyte Antigen 4) also known as CD152, is a protein which is expressed on the surface of Helper T cells and plays an important regulatory role in the immune system. CTLA4 is a member of the immunoglobulin superfamily, expressed on the surface of Helper T cells. CTLA4 transmits an inhibitory signal to T cells. CTLA4 is potentially therapeutic in auto-immune diseases4, such as rheumatoid arthritis, HIV, autoimmune thyroid disease, multiple sclerosis and may also be useful during organ transplantation and cancer treatment. Clone 9H10 antibody has been shown to promote T cell co-stimulation by blocking CTLA4 binding, allowing for CD28 binding.Gr-1 is a 21-25 kD protein also known as Ly-6G/Ly-6C. This myeloid differentiation antigen is a glycosylphosphatidylinositol (GPI)-linked protein expressed on granulocytes and macrophages. Clone RB6-8C5 antibody has been shown to inhibit the binding of the clone 1A8 antibody. Clone 1A8 monoclonal antibody reacts specifically with mouse Ly6G with no reported cross-reactivity with Ly6C.In vivo CTLA-4 neutralizationIn vivo depletion of Gr-1+ myeloid cells, Flow cytometry, Immunohistochemistry(Paraffin and Frozen), Western blotprotein A or Gprotein A or GThis antibody is stable for at least 2 months when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at -20°C or -80°C. Avoid repeated freeze thaw cycles.This antibody is stable for at least 2 months when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at -20°C or -80°C. Avoid repeated freeze thaw cycles.2-8°C with blue ice2-8°C with blue iceLot specific, generally ≥ 5.0 mg/mlLot specific, generally ≥ 5.0 mg/ml12 months from the date of receipt if stored as recommended12 months from the date of receipt if stored as recommendedPBS Buffer, PH 7.2, with no carrier protein, or preservatives.PBS Buffer, PH 7.2, with no carrier protein, or preservatives.0.2 μM filtered0.2 μM filtered≤ 1.0 EU/mg, by the LAL method≤ 1.0 EU/mg, by the LAL method0.990.99可替换BioXCell产品货号为BE0075